NCT05571527 is a NA clinical trial of Platelet Rich Plasma treatment in Genitourinary Syndrome of Menopause, sponsored by Kanuni Sultan Suleyman Training and Research Hospital.

Who is sponsoring NCT05571527?

NCT05571527 is sponsored by Kanuni Sultan Suleyman Training and Research Hospital.

What drugs are being tested in NCT05571527?

Interventions in NCT05571527: Platelet Rich Plasma treatment, Vaginal Hyaluronic Acid supplement.

What condition does NCT05571527 study?

NCT05571527 studies Genitourinary Syndrome of Menopause.

Is NCT05571527 still recruiting?

NCT05571527 is currently status unknown. Last updated 5 March 2024.

Last reviewed 2024-03-05 · How we verify

NCT05571527

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Vaginal Hyaluronic Acid Treatment Over Autologous Platelet Rich Plasma Treatment for Genitourinary Syndrome of Menopause

Status unknown NA Last updated 5 March 2024

What this trial tests

NA trial testing Platelet Rich Plasma treatment in Genitourinary Syndrome of Menopause in 60 participants. Status unknown.

Timeline

1 November 2023

Primary endpoint
1 March 2024

1 December 2024

Quick facts

Lead sponsor	Kanuni Sultan Suleyman Training and Research Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	1 November 2023
Primary completion	1 March 2024
Estimated completion	1 December 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Platelet Rich Plasma treatment — full drug profile →
Vaginal Hyaluronic Acid supplement — full drug profile →

Conditions studied

Genitourinary Syndrome of Menopause — all drugs for Genitourinary Syndrome of Menopause →

Sponsor

Kanuni Sultan Suleyman Training and Research Hospital

Who can join

45 and older, female only, with Genitourinary Syndrome of Menopause. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Genitourinary syndrome of menopause (GSM) is a collection of symptoms and signs caused by hypoestrogenic changes to the labia majora/minora, clitoris, vestibule/introitus, vagina, urethra, and bladder that occur in menopausal patients. Platelet-rich plasma is produced by collecting approximately 60-90 ml (4-6 tablespoons) of blood from the vein in patient's arm. The blood is spun using a centrifuge that separates the plasma and red blood cells. The treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet-rich plasma, etc. The observational cohort study will be used for the study design. Questionnaires, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used to evaluate the effectiveness and side effects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.
Palaia I, Caruso G, Di Donato V, Turetta C, et al · · 2024 · cited 6× · PMID 38497108 · DOI 10.3802/jgo.2024.35.e70

Verify or expand the search:

Other recruiting trials for Genitourinary Syndrome of Menopause

Currently open trials in the same condition.

NCT06873971 — Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause · NA · recruiting
NCT06007027 — Vaginal CO2 Laser Therapy for Genitourinary Syndrome in Breast Cancer Survivors · NA · recruiting
NCT06508788 — Combination of the Vaginal Laser With a Moisturizing and Repairing Niosomal Gel in the Treatment of Genitourinary Syndro · recruiting
NCT06925139 — Efficacy of Non-Ablative Radiofrequency on Vaginal and Sexual Health in Postmenopausal Women · NA · active not recruiting
NCT06028009 — PRP Injections for Genitourinary Syndrome of Menopause · NA · active not recruiting

Other Kanuni Sultan Suleyman Training and Research Hospital trials

Trials by the same sponsor.

NCT07519551 — Serum Myostatin and Irisin Levels in Postmenopausal Women: Association With Bone Mineral Density and Muscle Strength · not yet recruiting
NCT07480330 — Serum Neurofilament Light Chain Levels and Neuropathy Severity in Diabetic Polyneuropathy · not yet recruiting
NCT07425405 — Daily Screen Exposure and Preoperative Anxiety in Children Aged 2-5 Years · recruiting
NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
NCT07261436 — Performance Comparison of Large Language Models in TAP Block Ultrasound Interpretation · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05571527 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kanuni Sultan Suleyman Training and Research Hospital
Last refreshed: 5 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05571527.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing